Semaglutides are turning out to be transformative for obesity in the way that statins have been transformative for hypercholesterolemia and anti-hypertensives have been transformative for high blood pressure: they’re not only highly effective but have minimal side effects. From a public health standpoint, there’s every reason to allow Medicare and Medicaid coverage for semaglutides. But […]

Obesity is a risk factor for cancer, heart disease stroke and diabetes. Thus, drugs like semaglutides (Wegovy, Ozempic) don’t just reduce weight in the obese, they also reduce risk of cancer, heart disease, stroke and diabetes, which are huge health care burdens. It’s good to see that Medicare is finally coming to grips with this […]